About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 624 record(s)
Req # A-2023-000167
COVID-19 impact reports of GEN-Clozapine. All marketed strengths of GEN-Clozapine (Drug Identificatoin Number (DIN) #s, 02247243, 02247244, 02305003 and 02305011).Organization: Health Canada
October 2023
Req # A-2023-000301
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Clinical Practice (GCP) inspection of the Merck Canada facility in Kirkland, Quebec, for the Region of Alberta starting around 25 May 2021. Reference Number 182348.Organization: Health Canada
October 2023
Req # A-2023-000302
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Pharmacovigilance Practices (GVP) inspection of the Bausch & Lomb facility in Rochester, New York, United States of America starting around 6 December 2022. Reference Number 502442.Organization: Health Canada
October 2023
Req # A-2023-000303
Provide the disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Pharmacovigilance Practices (GVP) inspection of the Merck Canada facility in Kirkland, Quebec, starting around 7 November 2022. Reference Number 502785.Organization: Health Canada
October 2023
Req # A-2023-000383
All emails between members of the Scientific Advisory Committee on Health Products for Women and/or between members of the Scientific Advisory Committee on Health Products for Women and the committee’s secretariat on the topic of breast implants.Organization: Health Canada
October 2023
Req # A-2023-000455
Every final Harassment and Violence investigation report completed during the period of April 1, 2021 to March 31, 2023.Organization: Health Canada
October 2023
Req # A-2023-000458
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Manufacturing Practices (GMP) inspection of the Apotex facility on Signet Drive, Toronto, Ontario starting around 5 June 2017. Reference Number 501259.Organization: Health Canada
October 2023
Req # A-2023-000473
All relevant documents from the following workstreams: Workstream D: Pollinator protection and neonicotinoid pesticides; Workstream E: Pest control emerging technologies related to the Canada-United States Regulatory Cooperation Council (RCC) for pesticides 2019–2020.Organization: Health Canada
October 2023
Req # A-2023-000493
All correspondence between Health Canada and Dr. Robert Casper and/or Toronto Centre for Advance Reproductive Technology (TCART) related to the Ovu Science company and/or AUGMENT intervention or study.Organization: Health Canada
October 2023
Req # A-2023-000737
All documents submitted in the medical device license application, resulting in Acro Biotech's Medical Device Licence (MDL)#108387, be provided.Organization: Health Canada
October 2023